// App-Quantinova.ai

269 : In axial spondyloarthritis, magnitude of improved disease activity after six months of biologic disease-modifying treatment may be more relevant to short-term functional outcome than achieving an inactive disease state

Researchers

Presenter

  • Thomas Williams

Principal Investigators

  • Alison Wadeley

  • Charlotte Cavill

  • Mandy Freeth

  • Raj Sengupta

Medical Centers

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • College of Liberal Arts: Culture and Envirnoment, Bath Spa University, Bath, UNITED KINGDOM

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved